The treatment of NAFLD

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 5, 2005, Pages 299-304

  Trappoliere, M ^a   Tuccillo, C ^a   Federico, A ^a   Di Leva, A ^a   Niosi, M ^a   D'Alessio, C ^a   Capasso, R ^a   Coppola, F ^a   D'Auria, M ^a   Loguercio, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antifibrotic agents; Antioxidants; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIFIBROTIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; BETA CAROTENE; BETAINE; BIGUANIDE DERIVATIVE; CLOFIBRATE; GLUCURONIC ACID; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; NICOTINAMIDE; PHOSPHATIDYLCHOLINE; PIOGLITAZONE; PIRFENIDONE; ROSIGLITAZONE; SELENIUM; SIBUTRAMINE; SILIBININ; SILYMARIN; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

ARTICLE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; STELLATE CELL; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CYTOKINES; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER CIRRHOSIS; OBESITY; WEIGHT LOSS;

EID: 25844487704     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcohlic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
3. Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweigth and obesity adults. Arch Intern Med 1998; 158: 1855-1867.
4. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanism and significant for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597.
5. Clark JM, Brancati FL, Diehl AM. Nonalcholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.
6. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003, 34: 1-10.
7. Palmer M, Schaffner F. Effects of weight reduction on hepatic abnormalities in overweight patient. Gastroenterology 1990; 99: 1408-1413.
8. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with Weight loss. Hepatology 2004; 39: 1647-1654.
9. Loguercio C, De Girolamo V, de Sio I, et al. Non alcoholic fatty liver disease in an area of southern Italy: main clinical, histological and pathophysiological aspects. J Hepatol 2001; 35: 568-574.
10. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ, Kraegen EW. Mechanism of liver and muscle insulin resistance induced by chronic higth-fat feeding. Diabetes 1997; 46: 1768-1774.
11. Song YJ, Samawura M, Ikeda K, Igawa S, Yamori Y. Soluble dietary fibre improves insulin sensitivity by increasing muscle GLUT-4 content in stoke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2000; 27: 41-45.
12. Clarke SD, Baillie R, Jump DB, Nakamura MT. Fatty acid regulation of gene espression. Its role fuel partitioning and insulin resistance. Ann N Y Acad Sci 1997; 827: 178-187.
13. Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 intervention on insulin resistance. Arch Intern Med 1998; 158: 2477-2483.
14. Kang J, Robertson RJ, Hagber JM, et al. Effect of exercise intensity on glucose and insulin metabolism in obese individual and obese NIDDM patiens. Diabetes Care 1996; 19: 341-349.
15. Harrison SA, Finke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004: 20: 623-628.
16. Sanyal AJ, Cambpell Sargent C, Mirshai F, Rizzo WB, Clore JN. Nonalcholic steatohepatitis: association of insulin resistence and mitocondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
17. Mingrone G, De Gaetano A, Greco AV, et al. Reversibility of insulin resistance in obese diabetic patient: role of plasma lipids. Diabetologia 1997; 40: 599-605.
18. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-1017.
19. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
20. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893-894.
21. Nair S, Diehl Am, Wiseman M, Farr GH Jr, Perillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-28.
22. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
23. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycolic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis; a pilot study. Hepatology 1996; 23: 1464-1467.
24. Tokar JL, Berg CL. Therapeutic options in non-alcoholic fatty liver disease; Curr Treat Options Gastroenterol 2002; 5: 425-426.
25. Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97: 2144-2146.
26. Berg AH, Combs TP, Scherer PE. ACRP30 adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
27. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737.
28. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
29. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
30. Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145: 367-383.
31. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003; 3: 207-213.
32. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001; 35: 134-146.
33. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778.
34. Hasegawa T, Yoneda M, Nakwura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001: 15: 1667-1672.
35. Hiroko M, Kazuo I, Yuji N, Saburo H, Yukihiro I, Norifumi K. Sulfur-containing amino acids attenuate the development of liver fibrosis in rats through down-regulation of stellate cell activation. J Hepatol 2004; 40: 917-925.
36. Okuyama H, Shimahara Y, Kawada N. The hepatic stellate cells in the post-genomic era. Histol Histopathol 2002; 17: 487-495.
37. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451.
38. Eng FJ, Friedman SI. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000; 279: G7-G11.
39. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250.
40. Czaya MJ, Weiner FF, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-beta1 with hepatic fibrosis. J Cell Biol 1989; 108: 2477-2482.
41. Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992: 308: 267-270.
42. Oberhammer FA, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 1992; 89: 5408-5412.
43. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 2004; 36: 744-751.
44. Fuchs EC, Weyhenmeyer R, Weiner OH. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. Arzneimittelforschung 1997; 47: 1383-1387.
45. Di Sario A, Bendie F, Taffetani S, et al. Realsil, a new sylibin-phospatidylcoline complex, reduces dimethylnitrosamine-induced hepatic fibrosis in the rat. J Hepatol 2003; 38 (2 Suppl).
46. Federico A, Tuccillo C, Biscaglia G, et al. The effect of chronic treatment with silibinin on insulin-resistance and plasma markers of liver fibrosis in patient with chronic liver damage. Hepatology 2004; 40 (1 Suppl): 583A.
47. Federico A, Tuccillo C, Marone A, Niosi M and RealSilGroup Loguercio C. Chronic treatment with sylibin significantly improves insulin-resistance in patients with nonalcoholic fatty liver disease. Abs. Monothematic Conference - Non alcoholic steatohepatitis: from cell biology to clinical pratice-Estoril, Portugal september 17-18, 2004.